Hedge fund 'pounces' on 'weak' AMAG with $380mn takeover bid to derail Allos merger
This article was originally published in Scrip
Executive Summary
MSMB Capital Management, a New York-based hedge fund, is so displeased with the idea of a merger between AMAG and Allos Therapeutics that it has made an unsolicited bid for AMAG, for about $381 million.